We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The withdrawal of an antitrust lawsuit against Purdue Pharma concerning its pain treatment OxyContin is not expected to affect the company’s legal footing in other litigation, in which it remains confident it will prevail.
Mylan Laboratories lost its bid to launch generic Topamax capsules and tablets after a federal court barred the company from selling its version of the epilepsy treatment prior to late 2008.
A federal appeals court has invalidated a key patent held by Pfizer for its blockbuster high blood pressure treatment Norvasc,
the company said March 22.
The reversal of a U.S. district court’s decision that dismissed a legal action brought by Teva Pharmaceutical to launch generic Famvir may have positive implications for generic firms taking moves to avoid at-risk launches, according to legal sources.
The fate of Mylan Pharmaceuticals’ 180-day marketing exclusivity period for its recent launch of generic Norvasc may be answered in a little more than two weeks, according to terms of a court order blocking other generic firms from marketing their versions of the drug.
Moving to minimize the effect of generic competition for its blockbuster hypertension drug, Pfizer plans to authorize the sale of its own generic Norvasc, the company announced last week.
The Supreme Court is seeking advice from the U.S. government on whether it should review a federal antitrust lawsuit triggered by a reverse-payment deal that delayed the launch of generic tamoxifen.
A study claiming that two state pharmaceutical gift disclosure laws do not make payment information easily available to the public relied on inconsistent and mixed data, a top PhRMA official said.
Mylan Laboratories lost its bid to launch generic Topamax capsules and tablets after a federal court barred the company from selling its version of the epilepsy treatment prior to late 2008.
A federal appeals court has invalidated a key patent held by Pfizer for its blockbuster high blood pressure treatment Norvasc, the company said March 22.